tert-butyl 4-(2,4-difluorobenzoyl)piperazine-1-carboxylate | 1065586-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(2,4-difluorobenzoyl)piperazine-1-carboxylate
• 英文别名: t-butyl 4-(2,4-difluorobenzoyl)piperazine-1-carboxylate
• CAS: 1065586-35-7
• 化学式: C₁₆H₂₀F₂N₂O₃
• mdl: MFCD20039757
• 分子量: 326.343
• InChiKey: FCUZHQMEYWJPPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2,4-difluorobenzoyl)piperazine-1-carboxylate 在 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 3-(3-(4-(4-fluoro-2-(4-(6-fluorobenzo[d]isooxazol-3-yl)piperazin-1-yl)benzoyl)piperazine-1-yl)propyl)-9-hydroxy-2-phenyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
  参考文献：
  名称：

  吡啶并嘧啶类化合物及其应用

  摘要：

  本发明涉及一种式I的化合物、其对映异构体、外消旋体或其盐，以及其用于治疗肿瘤的用途。

  公开号：

  CN109748914B
• 作为产物：
  描述：

  N-Boc-哌嗪 、 2,4-二氟苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以92 %的产率得到tert-butyl 4-(2,4-difluorobenzoyl)piperazine-1-carboxylate
  参考文献：
  名称：

  GPR6 INVERSE AGONISTS

  摘要：

  Provided herein, is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Cy, Hy, X, Y, Ra, Rb, Rc, and Rdare defined herein as well as compositions and methods of use thereof.

  公开号：

  WO2024036288A2

文献信息

• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Moorman Allan R.

  公开号：US20080242672A1

  公开（公告）日：2008-10-02

  The present invention provides compounds of the formula wherein R 1 and R 2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A 2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A 2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了以下式的化合物 其中R 1 和R 2 的含义如规范中所定义。式(I)的化合物是腺苷A 2A 受体拮抗剂，因此可用于治疗由腺苷A 2A 受体活性介导的疾病和病症。这些疾病包括但不限于中枢神经系统疾病，如抑郁症、认知功能疾病和神经退行性疾病，如帕金森病、老年性痴呆症、精神病和中风。本发明的化合物还可用于治疗注意力相关障碍，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合征，例如肌张力障碍、不安坐立、假性帕金森症和迟发性运动障碍，以及异常运动障碍，如不宁腿综合征（RLS）和睡眠中期肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在硬皮病等疾病中的皮肤纤维化；以及对成瘾行为的缓解。特别是，本发明的化合物可用于改善由帕金森病等神经退行性疾病引起的运动障碍。
• Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
  申请人：King Pharmaceuticals Research and Development, Inc.

  公开号：US07691869B2

  公开（公告）日：2010-04-06

  The present invention provides compounds of the formula wherein R1 and R2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了符合以下公式的化合物，其中R1和R2的含义如本说明书中所定义。公式（I）的化合物是腺苷A2A受体拮抗剂，因此可用于治疗由腺苷A2A受体活性介导的疾病和症状。这些疾病包括但不限于中枢神经系统疾病，如抑郁症、认知功能障碍和神经退行性疾病，如帕金森病、老年性痴呆症或精神病和中风。本发明的化合物还可用于治疗注意力相关障碍，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合症，如肌张力障碍、不安腿综合症、假性帕金森综合症和迟发性运动障碍，以及异常运动障碍，如不安腿综合症（RLS）和睡眠时期肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在类硬化症等疾病中的皮肤纤维化；以及缓解成瘾行为。特别是，本发明的化合物可用于改善由神经退行性疾病如帕金森病引起的运动障碍。
• Adenosine A2A receptor antagonists
  申请人：King Pharmaceuticals Research and Development, Inc.

  公开号：US07723343B2

  公开（公告）日：2010-05-25

  The present invention provides compounds of the formula wherein R1 and R2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了以下式子的化合物： 其中，R1和R2在规范中定义。式（I）的化合物是腺苷A2A受体拮抗剂，因此可用于治疗由腺苷A2A受体活性介导的疾病和症状。这些病症包括但不限于中枢神经系统疾病，如抑郁症、认知功能障碍和神经退行性疾病，如帕金森病、老年性痴呆症、精神病和中风。本发明的化合物也可用于治疗与注意力相关的疾病，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合征，例如肌张力障碍、不安腿综合征、假性帕金森综合征和迟发性运动障碍，以及异常运动障碍，如不宁腿综合征（RLS）和睡眠中周期性肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在类硬化病等疾病中的皮肤纤维化；以及缓解成瘾行为。特别是，本发明的化合物可用于改善由神经退行性疾病（如帕金森病）引起的运动障碍。
• US7691869B2
  申请人：——

  公开号：US7691869B2

  公开（公告）日：2010-04-06
• US7723343B2
  申请人：——

  公开号：US7723343B2

  公开（公告）日：2010-05-25